Summary of patient characteristics
Patient no. . | BM/PB . | White blood cell counts, × 109/L . | % blasts In PB . | % CD34 . | Flt3-ITD . | FAB . | Karyotype . | Risk group . | C/EBPα transduction . | EMSA . | Q-PCR . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | PB | 30 | 90 | 14 | − | M2 | t(8;21) | Good | + | + | — |
2 | PB | 15 | 30 | 30 | + | M1 | Normal | Intermediate | + | + | + |
3 | PB | 60 | 60 | 14 | + | M5 | Normal | Intermediate | + | + | — |
4 | PB | 20 | 50 | 70 | − | M1 | +3q, −7, −10 | Poor | + | + | — |
5 | PB | 100 | 90 | 2 | − | M1 | Normal | Intermediate | + | — | — |
6 | PB | 70 | 86 | 7 | − | M4 | t(6;11), (q27;23) | Poor | + | + | — |
7 | PB | 100 | 80 | 1 | + | M5 | Normal | Intermediate | + | — | — |
8 | PB | 84 | 80 | 5 | + | M5b | Normal | Intermediate | + | + | — |
9 | PB | 47 | 36 | 1 | + | M5 | Normal | Intermediate | + | — | — |
10 | PB | 22 | 72 | 28 | + | M5 | Normal | Intermediate | + | + | — |
11 | PB | 63 | 67 | 66 | + | M1 | t(6;9), trisomy 13 | Poor | + | + | + |
Patient no. . | BM/PB . | White blood cell counts, × 109/L . | % blasts In PB . | % CD34 . | Flt3-ITD . | FAB . | Karyotype . | Risk group . | C/EBPα transduction . | EMSA . | Q-PCR . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | PB | 30 | 90 | 14 | − | M2 | t(8;21) | Good | + | + | — |
2 | PB | 15 | 30 | 30 | + | M1 | Normal | Intermediate | + | + | + |
3 | PB | 60 | 60 | 14 | + | M5 | Normal | Intermediate | + | + | — |
4 | PB | 20 | 50 | 70 | − | M1 | +3q, −7, −10 | Poor | + | + | — |
5 | PB | 100 | 90 | 2 | − | M1 | Normal | Intermediate | + | — | — |
6 | PB | 70 | 86 | 7 | − | M4 | t(6;11), (q27;23) | Poor | + | + | — |
7 | PB | 100 | 80 | 1 | + | M5 | Normal | Intermediate | + | — | — |
8 | PB | 84 | 80 | 5 | + | M5b | Normal | Intermediate | + | + | — |
9 | PB | 47 | 36 | 1 | + | M5 | Normal | Intermediate | + | — | — |
10 | PB | 22 | 72 | 28 | + | M5 | Normal | Intermediate | + | + | — |
11 | PB | 63 | 67 | 66 | + | M1 | t(6;9), trisomy 13 | Poor | + | + | + |
Blasts isolated from bone marrow (BM) or peripheral blood (PB). AMLs were categorized according to the French-American-British (FAB) classification. Positivity for Flt3-ITD is indicated as well as CD34 percentage, karyotype, and risk group. The right 3 columns indicate the experiments performed with the AMLs.
— indicates not done.